These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32729743)

  • 41. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
    Whayne TF
    Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs.
    López-Miranda J; Pedro-Botet J
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():46-52. PubMed ID: 33966813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Statin intolerance].
    Graversen CB; Larsen ML; Schmidt EB
    Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New insights into managing symptoms during statin therapy.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of statin therapy.
    Adhyaru BB; Jacobson TA
    Nat Rev Cardiol; 2018 Dec; 15(12):757-769. PubMed ID: 30375494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
    Rubba P; Marotta G; Gentile M
    Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.
    Katsiki N; Athyros VG; Karagiannis A
    Curr Vasc Pharmacol; 2016; 14(6):523-533. PubMed ID: 26916398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NLA Task Force on Statin Safety--2014 update.
    Jacobson TA
    J Clin Lipidol; 2014; 8(3 Suppl):S1-4. PubMed ID: 24793438
    [No Abstract]   [Full Text] [Related]  

  • 55. The Role of Nutraceuticals in Statin Intolerant Patients.
    Banach M; Patti AM; Giglio RV; Cicero AFG; Atanasov AG; Bajraktari G; Bruckert E; Descamps O; Djuric DM; Ezhov M; Fras Z; von Haehling S; Katsiki N; Langlois M; Latkovskis G; Mancini GBJ; Mikhailidis DP; Mitchenko O; Moriarty PM; Muntner P; Nikolic D; Panagiotakos DB; Paragh G; Paulweber B; Pella D; Pitsavos C; Reiner Ž; Rosano GMC; Rosenson RS; Rysz J; Sahebkar A; Serban MC; Vinereanu D; Vrablík M; Watts GF; Wong ND; Rizzo M;
    J Am Coll Cardiol; 2018 Jul; 72(1):96-118. PubMed ID: 29957236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
    Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statin-Associated Muscle Disease: Advances in Diagnosis and Management.
    Taylor BA; Thompson PD
    Neurotherapeutics; 2018 Oct; 15(4):1006-1017. PubMed ID: 30251222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].
    Bertomeu-Martínez V
    Medwave; 2016 Dec; 16(Suppl4):e6825. PubMed ID: 28055995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipids: a personal view of the past decade.
    Katsiki N; Mikhailidis DP
    Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.